Vor Biopharma Inc. (VOR)

Market Cap	262.14M
Revenue (ttm)	n/a
Net Income (ttm)	-118.60M
Shares Out	126.64M
EPS (ttm)	-1.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,773,403
Open	2.090
Previous Close	2.090
Day's Range	2.015 - 2.120
52-Week Range	0.131 - 3.290
Beta	2.06
Analysts	Buy
Price Target	3.77 (+82.13%)
Earnings Date	Aug 15, 2025

About SATX

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2;...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 159
• Stock Exchange: NASDAQ
• Ticker Symbol: VOR
• Website: https://www.vorbio.com

Analyst Summary

According to 7 analysts, the average rating for VOR stock is "Buy." The 12-month stock price target is $3.77, which is an increase of 82.13% from the latest price.

Price Target

$3.77

(82.13% upside)

Analyst Consensus: Buy